Research has shown that deletions of PTEN occur at a very high frequency in prostate cancer.1 Other studies have demonstrated an association between decreased PTEN protein expression and a higher Gleason grade and advanced tumor stage.2 In a study by Yoshimoto it was demonstrated that the presence of PTEN genomic losses are frequent at diagnosis and are a significant prognostic marker for the subsequent development of clinically advanced disease.3 The TMPRSS2: ERG fusion gene, is a transcription promoter that contributes to the proliferation and invasive capacity of cancer cells.4 The combination of PTEN loss and ERG overexpression has been associated with aggressive disease.5